Chemical Biology Laboratory, National Cancer Institute, Frederick, Maryland 21702, United States.
J Med Chem. 2021 May 13;64(9):5291-5322. doi: 10.1021/acs.jmedchem.1c00172. Epub 2021 Apr 27.
Cells of the immune system utilize multiple proteases to regulate cell functions and orchestrate innate and adaptive immune responses. Dysregulated protease activities are implicated in many immune-related disorders; thus, protease inhibitors have been actively investigated for pharmaceutical development. Although historically considered challenging with concerns about toxicity, compounds that covalently modify the protease active site represent an important class of agents, emerging not only as chemical probes but also as approved drugs. Here, we provide an overview of technologies useful for the study of proteases with the focus on recent advances in chemoproteomic methods and screening platforms. By highlighting covalent inhibitors that have been designed to target immunomodulatory proteases, we identify opportunities for the development of small molecule immunomodulators.
免疫系统利用多种蛋白酶来调节细胞功能并协调先天和适应性免疫反应。蛋白酶活性失调与许多免疫相关疾病有关;因此,蛋白酶抑制剂一直是药物开发的热门研究对象。虽然这些抑制剂在历史上由于毒性问题而被认为具有挑战性,但共价修饰蛋白酶活性位点的化合物代表了一类重要的药物,不仅作为化学探针,而且作为已批准的药物出现。在这里,我们提供了一种用于研究蛋白酶的技术概述,重点介绍了化学蛋白质组学方法和筛选平台的最新进展。通过突出设计用于靶向免疫调节蛋白酶的共价抑制剂,我们确定了小分子免疫调节剂开发的机会。